Bill and Scott take a look at recent Chinese export restrictions on U.S. companies, examine the USTR&#x27;s visits to India and Uzbekistan, and dig into a newly announced U.S. probe of German pharmaceutical pricing.

Chinese Export Restrictions, USTR in India and Uzbekistan, and German Pharmaceutical Pricing

The Trade Guys

I'm Scott. I'm Bill. And we're The Trade Guys. We're listening to The Trade Guys, a podcast produced by CSIS, where we talk about trade in terms that everyone can understand. I'm Alex Kisling, and I'm here with Scott Miller and Bill Reich, the CSIS Trade Guys.

Thanks for listening to The Trade Guys. On today's episode, we take a look at recent Chinese export restrictions on US companies, examine the US trade representatives' visits to India and Uzbekistan, and dig into a newly announced US probe of German pharmaceutical pricing. All that and more on today's episode of The Trade Guys.

Trade Guys, I want to start this week with an update on a Supreme Court case that we discussed a few weeks ago. And this is a case that just had a ruling come down a few days ago, the Alien Tort Statute. And Bill, I know you've been tracking this. So before we get into our other topics, I wanted to turn to you for a readout of what the court said. Yes, just a short note, and we can put it in because there's no customs refund update this week. And so we're going to have a court update instead.

This was a case that has followed many in the Alien Tort Statute, which we did talk about before. It's called Cisco v. Doe. And the allegation concerned whether or not Cisco had aided and abetted the Chinese in setting up a surveillance system that, among other things, persecuted the Falun Gong. The court never addressed the merits of that particular allegation.

Chinese Export Restrictions, USTR in India and Uzbekistan, and German Pharmaceutical Pricing

Read the full transcript

The candid version is on a podcast,
not the earnings call.

Chinese Export Restrictions, USTR in India and Uzbekistan, and German Pharmaceutical Pricing

Read the full transcript

The candid version is on a podcast, not the earnings call.

The candid version is on a podcast,
not the earnings call.